Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

This is a multicenter, open-label, non-randomized, single-arm clinical trial. Patients with relapsed/refractory multiple myeloma accompanied by extramedullary infiltration will receive BCMA - GPRC5D CAR-T cell therapy. The primary objective is to prospectively evaluate the safety of dual-targeting BCMA and GPRC5D CAR - T cell therapy for extramedullary infiltration in relapsed/refractory multiple myeloma. The primary endpoints are to assess the type and incidence of dose-limiting toxicity (DLT) within one month after the reinfusion of BCMA-GPRC5D CAR-T cells in patients, as well as the incidence and severity of adverse events within one month after the reinfusion. It is expected that no more than 18 participants will be recruited.

NCT Number	NCT07003568
Lead Sponsor	Beijing GoBroad Hospital Collaborators: Shanghai Liquan Hospital, Ruijin Hospital
Conditions	Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment	18 participants
Start Date	2025-05-25
Primary Completion	2027-05-25 (estimated)
Study Completion	2027-06-25 (estimated)
Updated on ClinicalTrials.gov	2025-11-26